Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether AeroVanc treatment is safe and effective in
reducing the number of MRSA colony forming units in the lungs of cystic fibrosis patients.
Phase:
Phase 2
Details
Lead Sponsor:
Savara Inc.
Collaborators:
Cystic Fibrosis Foundation Cystic Fibrosis Foundation Therapeutics Synteract, Inc.